Evidence map›Paper›PMID 30778346›Full record

ArticleFrontiers in immunology2019

Recombinant Sialyltransferase Infusion Mitigates Infection-Driven Acute Lung Inflammation.

Mehrab Nasirikenari, Amit A Lugade, Sriram Neelamegham, Zhongwei Gao, Kelley W Moremen, Paul N Bogner, Yasmin Thanavala, Joseph T Y Lau

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Hyper α2,6-Sialylation Promotes CD4Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Mehrab NasirikenariDepartment of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
Amit A LugadeDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
Sriram NeelameghamDepartment of Chemical and Biomedical Engineering, University at Buffalo, Buffalo, NY, United States.
Zhongwei GaoThe Complex Carbohydrate Research Center, University of Georgia, Athens, GA, United States.
Kelley W MoremenThe Complex Carbohydrate Research Center, University of Georgia, Athens, GA, United States.
Paul N BognerDepartment of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
Yasmin ThanavalaDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
Joseph T Y LauDepartment of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
Roswell Park Comprehensive Cancer Center · USUniversity of Georgia · USUniversity at Buffalo, State University of New York · US

Funding

REGULATION OF LACTOSAMINYL GLYCAN BIOSYNTHESIS IN HEMATOPOIETIC CELLSP01HL107146 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI RHEINHOLD, VERN · 2011 to 2017
$17.7M
TR&D3. Approaches to Proteoglycan Function at Biochemical and Cellular LevelsP41GM103390 · NIGMS · UNIVERSITY OF GEORGIA · PI MOREMEN, KELLEY W. · 2012 to 2019
$14.5M
Recombinant Production of Glycosylation Enzymes for Biochem/Structural StudiesP01GM107012 · NIGMS · UNIVERSITY OF GEORGIA · PI MOREMEN, KELLEY · 2013 to 2017
$7.5M
Systems Biology of GlycosylationR01HL103411 · NHLBI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI NEELAMEGHAM, SRIRAM · 2011 to 2025
$7.1M
ST6Gal-1 Sialyltransferase in InflammationR01AI140736 · NIAID · ROSWELL PARK CANCER INSTITUTE CORP · PI LAU, JOSEPH TY · 2018 to 2021
$3.9M
ST6Gal Sialyltransferase in Innate and Adaptive Immune ResponseR01AI056082 · NIAID · ROSWELL PARK CANCER INSTITUTE CORP · PI LAU, JOSEPH TY · 2006 to 2015
$3.6M
Origin of N-Glycan Site-Specific HeterogeneityR01GM130915 · NIGMS · UNIVERSITY OF GEORGIA · PI KANNAN, NATARAJAN, MOREMEN, KELLEY W. · 2019 to 2022
$3.4M
NHLBI NIH HHS P01 HL107146NHLBI NIH HHS R01 HL103411NIAID NIH HHS R01 AI056082NIAID NIH HHS R01 AI140736NIGMS NIH HHS P01 GM107012NIGMS NIH HHS P41 GM103390NIGMS NIH HHS R01 GM130915
6 · The paper itself

Abstract

Inappropriate inflammation exacerbates a vast array of chronic and acute conditions with severe health risks. In certain situations, such as acute sepsis, traditional therapies may be inadequate in preventing severe organ damage or death. We have previously shown cell surface glycan modification by the circulating sialyltransferase ST6Gal-1 regulates

Indexed as

Acute DiseaseAnimalsAnti-Inflammatory Agents, Non-Steroidalbeta-D-Galactoside alpha 2-6-SialyltransferaseBiomarkersCytokinesDisease Models, AnimalInflammation MediatorsInfusions, IntravenousMiceMice, TransgenicNeutrophilsPneumoniaPrognosisRecombinant ProteinsSeverity of Illness IndexAnti-Inflammatory Agents, Non-Steroidalbeta-D-Galactoside alpha 2-6-SialyltransferaseBiomarkersCytokinesInflammation MediatorsRecombinant ProteinsSialyltransferasesairwayextrinsic glycosylationinfectioninflammationsialylationST6Gal-1

Identifiers

PMID30778346
PMCPMC6369197
OpenAlexW2913172208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.